Carboplatin

Alias: JM-8; NSC-241240; JM8; NSC241240; JM 8; NSC 241240; CBDCA; Carboplatin Hexal; Carboplatino; US trade names: Paraplat; Paraplatin; Foreign brand names: Blastocarb; Carboplat; Carbosin; Carbosol; Carbotec; Displata; Ercar; Nealorin; Novoplatinum; Paraplatin AQ; Paraplatine; Platinwas; Ribocarbo

Cat No.:V1425 Purity: ≥98%

COA Product Data Instructions for use SDS

Carboplatin Chemical Structure CAS No.: 41575-94-4
Product category: DNA(RNA) Synthesis

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
100mg
250mg
500mg
1g
2g
5g
10g
Other Sizes

ADD TO CART CHECKOUT BULK INQUIRY

1-708-310-1919 sales@invivochem.com

Official Supplier of:

Business Relationship with 5000+ Clients Globally
Major Universities, Research Institutions, Biotech & Pharma
Citations by Top Journals: Nature, Cell, Science, etc.

Top Publications Citing lnvivochem Products

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Purity & Quality Control Documentation

Current batch：

Purity: ≥98%

COA

MSDS

NMR

Instructions

Product Description
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Clinical Trial Information
Biological Data

Product Description

Carboplatin (formerly known as JM-8, CBDCA, NSC-241240; Paraplat; Paraplatin; Blastocarb; Carboplat; Carbosin; Carbosol; Carbotec; Displata; Ercar) is an approved anticancer drug that acts as a DNA synthesis inhibitor by binding to DNA (DNA alkylator) and interfering with the cell's repair mechanism in cancer cells. It is used to treat a few types of cancer, primarily head, neck, and ovarian cancers. It undergoes intracellular activation to generate reactive platinum complexes that attach to nucleophilic sites in DNA, including GC-rich regions, to create DNA-protein cross-links as well as intrastrand and interstrand cross-links. These effects of carboplatin on DNA and proteins lead to cell growth inhibition and apoptosis.

Biological Activity I Assay Protocols (From Reference)

Targets

DNA Alkylator

ln Vitro

In vitro activity: Carboplatin shows a suppressive effect on the growth of cells in a panel of human ovarian cancer cell lines, SKOV3, IGROV-1, and A2780 cells, with IC50 values of 2.2 μM, 12.4 μM, and 6.1 μM, respectively.[1] Additionally, lung carcinoid cell lines such as UMC-11, H727, and H835 cells demonstrate the anti-proliferative activities of carboplatin, with IC50 values of 36.4 μM, 3.4 μM, and 35.8 μM, respectively.[2]

ln Vivo

Carboplatin (60 mg/kg intraperitoneally) administered as a single agent in A2780 tumor xenografts exhibits a moderate antitumor effect, with day 6 tumor weights (T/C) of 67% and relative tumor volumes of 8.4 versus 11.9 on that day.[1] In comparison to the vehicle group, carboplatin treatment causes a 42% reduction in tumor mass and delays the growth of the tumor in the VC8 (Brca2-deficient) xenografts.[3]

Cell Assay

3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Ovarian cancer cells bearing the exponential growth markers A2780, SKOV3, IGROV-1, and HX62 are cultured in 96-well plates. To allow for three to four doubling times, a range of drug concentrations are added, and the plates are then incubated for 72 hours. Every experiment is run in three duplicates. Assays for sulforhodamine B (SRB): A2780 cells that are growing exponentially are plated in 96-well microtitre plates. In studies looking into concurrent exposure, cells are subjected to 96 hours of exposure to escalating concentrations of both medications. Cells are exposed to escalating concentrations of 17-AAG or carboplatin for a duration of 24 hours in order to conduct experiments examining the impact of exposure sequence. In order to give the A2780 cells at least one doubling time (18–24 hours), a 24-hour exposure period to the first agent was selected. The medium is then replaced after the cells are cleaned using sterile phosphate buffered saline. Subsequently, the medium or second medication, which the cells were not exposed to during the first 24 hours, is added and left for 96 hours. Every experiment is run in three duplicates. The well-established principles of the median effect analysis method are applied to the analysis of combination study results. An internal spreadsheet is used to calculate the combination's effects.

Animal Protocol

Mice: In female athymic NCr nude mice (nu/nu), the A2780 human ovarian cancer cell line is cultivated as a subcutaneous xenograft by injecting 4 × 10⁶ cells into each flank. Six mice per group are randomly assigned to receive treatment with either a control vehicle (43% ethanol, 33% polypropylene glycol, and 24% cremaphor diluted 1:7 with sterile water) days 1-4, 80 mg/kg intraperitonially (17-AAG), 60 mg/kg IP day 0 of carboplatin, or a combination of both (17-AAG, 80 mg/kg IP days 1-4) and Carboplatin, 60 mg/kg IP day 0). Tumor growth is measured three times per week, and volumes are computed using the following verified formula: volume = 4.19 × (a/4 + b/4)³, where a represents the longer diameter and b the shorter. Next, tumor volumes are expressed as a percentage of the volume at treatment initiation, or relative tumor volume.

References

[1]. Cancer Chemother Pharmacol . 2008 Oct;62(5):769-78.

[2]. Clin Transl Oncol . 2011 Jan;13(1):43-9.

[3]. Mol Cancer Ther . 2012 Sep;11(9):1948-58.

[4]. Clin Cancer Res . 2004 Mar 1;10(5):1633-44.

[5]. Anticancer Res . 2011 Sep;31(9):2713-22.

[6]. Cancer Res . 2014 Jul 15;74(14):3913-22.

[7]. Br J Cancer. 1995 Dec; 72(6): 1406–1411.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula

C6H12N2O4PT

Molecular Weight

371.25

Exact Mass

371.04

Elemental Analysis

C, 19.41; H, 3.26; N, 7.55; O, 17.24; Pt, 52.55

CAS #

41575-94-4

Related CAS #

41575-94-4

Appearance

White solid powder

SMILES

C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]

InChi Key

VSRXQHXAPYXROS-UHFFFAOYSA-N

InChi Code

InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2

Chemical Name

azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)

Synonyms

JM-8; NSC-241240; JM8; NSC241240; JM 8; NSC 241240; CBDCA; Carboplatin Hexal; Carboplatino; US trade names: Paraplat; Paraplatin; Foreign brand names: Blastocarb; Carboplat; Carbosin; Carbosol; Carbotec; Displata; Ercar; Nealorin; Novoplatinum; Paraplatin AQ; Paraplatine; Platinwas; Ribocarbo

HS Tariff Code

2931.90.9051

Storage

Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)

DMSO: <1 mg/mL

Water: ~14 mg/mL (~37.7 mM)

Ethanol: <1 mg/mL

Solubility (In Vivo)

Solubility in Formulation 1: 10 mg/mL (26.94 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).

Solubility in Formulation 2: Water: 14 mg/mL

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.6936 mL	13.4680 mL	26.9360 mL
	5 mM	0.5387 mL	2.6936 mL	5.3872 mL
	10 mM	0.2694 mL	1.3468 mL	2.6936 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Calculate Reset

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculate Reset

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Calculate Reset

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate Reset

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculate Reset

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04440358	Active Recruiting	Device: Exablate BBBD Drug: Carboplatin	Recurrent Glioblastoma	InSightec	October 13, 2020	Phase 1 Phase 2
NCT02436993	Active Recruiting	Drug: Carboplatin Drug: Paclitaxel	Breast Carcinoma	University of California, Irvine	April 2015	Phase 2
NCT03414684	Active Recruiting	Drug: Carboplatin Drug: Nivolumab	Breast Cancer	Dana-Farber Cancer Institute	January 30, 2018	Phase 2
NCT02531932	Active Recruiting	Drug: Carboplatin Drug: Everolimus	Breast Cancer	Amy Tiersten	December 16, 2015	Phase 2
NCT02547987	Active Recruiting	Drug: Docetaxel Drug: Carboplatin	Breast Cancer	Mothaffar Rimawi	November 1, 2015	Phase 2

Biological Data

Comparison of the effect of DMSO on the biological activity of cisplatin, carboplatin and oxaliplatin. Cancer Res . 2014 Jul 15;74(14):3913-22.
Comparison of the effect of DMSO on cisplatin, carboplatin and oxaliplatin-mediated DNA damage and cell death. Cancer Res . 2014 Jul 15;74(14):3913-22.
The mTOR inhibitor RAD001 sensitized different breast cancer cell lines to the cytotoxic effect of carboplatin. Anticancer Res . 2011 Sep;31(9):2713-22.

The combination of low concentrations of carboplatin and RAD001 resulted in the alteration of cell-cycle related proteins after long-term culture in MCF-7 and BT-474 cell lines. Anticancer Res . 2011 Sep;31(9):2713-22.

Effects of dexamethsone (DEX) on antitumor activity of carboplatin and gemcitabine chemotherapy in nude mice bearing human lung cancer A549 or H1299 xenografts. Clin Cancer Res . 2004 Mar 1;10(5):1633-44.

In vivo efficacy of ABT-888 in combination with carboplatin in Brca2 isogenic CHO xenograft models. Mol Cancer Ther . 2012 Sep;11(9):1948-58.
Cell death of BRCA and BRCA-complemented cell lines after treatment with ABT-888, carboplatin, or ABT-888/carboplatin combination. Mol Cancer Ther . 2012 Sep;11(9):1948-58.